By: Jessica Daniels
BlackDoctor
https://blackdoctor.org/
For many years, bladder cancer treatment followed a “one-size-fits-all” approach. Today, we have entered the era of precision medicine. This means doctors can look at the unique genetic makeup of your specific tumor to find “weak spots” and treat them with targeted therapies.
A major focus of this breakthrough is a group of proteins called FGFR, specifically FGFR3.
What is FGFR3 and Why is it a Target?
FGFR3 (Fibroblast Growth Factor Receptor 3) acts like a “growth switch” on the surface of cells. In a healthy body, it helps control cell division. In many bladder cancers, however, the gene for FGFR3 gets “stuck” in the ON position, signaling cancer cells to multiply and spread uncontrollably.
Key Research Findings on FGFR3:
- The Switch in Progression: Recent studies show that FGFR3 is extremely common (over 70 percent) in early, non-muscle-invasive bladder cancer. However, as the cancer becomes more aggressive and invades the muscle (MIBC), the expression of FGFR3 often drops significantly.
- Biological Switching: This reduction isn’t random; it’s part of a biological “switch” that makes the cancer harder to treat.
Molecular Testing: Identifying Your “Cancer ID Card”
To know if you can benefit from targeted treatments, your doctor must first identify the unique markers of your tumor through molecular testing (also called genomic profiling).
- What it is: A lab analysis of your tumor tissue or blood to look for specific “spelling errors” in your DNA (mutations), fusions, or protein levels.
- Testing Methods:
- Tissue Biopsy: Testing a piece of the tumor removed during surgery.
- Liquid Biopsy (ctDNA): A revolutionary blood test that looks for “circulating tumor DNA.” This can find microscopic traces of cancer—known as minimal residual disease—even when scans look clear.
Experts now suggest that every patient with advanced bladder cancer should have a molecular profile at the time of diagnosis to ensure no treatment options are missed.
Targeted and Personalized Breakthroughs
Beyond FGFR3, several other advancements are helping patients stay cancer-free longer by matching the right treatment to the right patient:
- Blocking the Growth Signal: Targeted therapies specifically designed for FGFR3 have been shown to reduce the risk of death by 36 percent in patients with certain genetic alterations compared to standard chemotherapy.
- Preventing Recurrence After Surgery: For those who have undergone radical surgery, certain immunotherapies (which boost the immune system) given for one year can nearly double the time spent cancer-free. This is especially effective for patients whose tumors express a protein called PD-L1.
- Monitoring with Blood Tests: Landmark studies have shown that blood tests (ctDNA) can guide care after surgery. Patients who test positive for cancer traces benefit significantly from starting therapy early, while those who stay negative may be able to avoid extra treatment and its side effects.
- The “Guided Missile” Approach: For patients who test positive for a protein called HER2, new treatments act like guided missiles, delivering therapy directly to the cancer cells while sparing healthy tissue.
Summary Checklist for Your Next Appointment
Because these treatments depend on your tumor’s specific “biomarkers,” you are your own best advocate. Ask your oncology team:
- “Has my tumor undergone molecular profiling for markers like FGFR3, HER2, and PD-L1?”
- “Does my cancer have the FGFR3 mutation that would make me a candidate for targeted therapy?”
- “Should we use a blood test (ctDNA) to check for remaining cancer cells after my surgery?”
- “Are there options to receive treatment both before and after my surgery to improve my long-term outlook?”
